Entecavir Therapy For Patients With Chronic Hepatitis B And The Analysis Of Inlfuencing Factors

Objective: To evaluate the efficacy and analysis influencing factor of response totherapy with entecavir in patients with chronic hepatits B.Materials and Methods: A total of nucleoside-naive62patients with chronic hepatitisB were collected, who were diagnosed and excluded other diseases. Allnucleoside-naive patients were treated with ETV0.5mg per day. Lasting more then96weeks. Observe HBV DNA quantitative, liver function, serum markers of hepatitis Bvirus in the treatment for24weeks,48weeks and96weeks. Data were analyzed bySPSS13.0software.Results: In all62patients, the HBV DNA negative rates (<1×103copies/ml) were75.8%,83.3%and93.2%, at week24,48and96. The rate of ALT normalization (<or=1x upper limit of normal), at week24and48, was70.4%and80.8%, respectively. In42patients with HBeAg-positive, at week24and48, the rate of HBeAg loss was2.4%and5%, respectively. HBeAg seroconversion were achieved by0％and2.5％of patients,at week24and48. The HBV DNA negative rates of the baseline ALT<2×the upperlimit of normal value (ULN) group was detcted41.7%in compare with the baselineALT≥2×ULN group was71.1%at week24, which had no statistically significance(P<0.05). At week48and96, the HBV DNA negative rates of the baselineALT<2×ULN group were65.2%and77.3%compared with83.8%and94.4%in thebaseline ALT≥2×ULN group, there was no statistically significance in two groups.Virological response rate was67.6%(41/62) at week24, HBV-DNA negative rates in the virological response at week24were97.6%and100%compared with42.9%and72.2%in the virological negative response at week24group, at week48and96.HBV-DNA<10~7copies/ml and≥10~7copies/ml in two groups were detected at week24,48and96, HBV-DNA negative rates were85.7%and56.1%(P=0.02),90.5%and69.2%(P=0.125),95.2%and85.7%(P=0.807). Virological breakthrough case has not bedetected.Obvious adverse reaction has not broken when all the patients were treated for96weeks, without virological breakthrough and rebound cases. Liver cirrhosis and livercancer were not found in all cases.Conclusion: Entecavir was effective to patients with chronic hepatitis B. Earlytherapeutic effect was better for the patients with baseline ALT≥2×ULN andHBV-DNA<10~7copies/ml, long-term efficacy was insignificant to the patients withlong-term threatment. Virological response at week24was in close touch withlong-term therapeutic effect, which could provid evidence for long-term therapeuticeffects of Entecavir.